Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.

Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N.

Cancer Res. 1999 Dec 15;59(24):6145-52.

2.
3.

Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.

Loganzo F Jr, Dosik JS, Zhao Y, Vidal MJ, Nanus DM, Sudol M, Albino AP.

Oncogene. 1993 Oct;8(10):2637-44.

PMID:
7690926
4.

Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.

Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE.

Oncogene. 2002 Nov 21;21(53):8075-88.

5.

The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.

Tatton L, Morley GM, Chopra R, Khwaja A.

J Biol Chem. 2003 Feb 14;278(7):4847-53.

6.

Expression of C-terminal src kinase in human colorectal cancer cell lines.

Watanabe N, Matsuda S, Kuramochi S, Tsuzuku J, Yamamoto T, Endo K.

Jpn J Clin Oncol. 1995 Feb;25(1):5-9.

PMID:
7533218
7.
8.
9.
10.

Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.

Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R, Yu H.

Oncogene. 2002 Oct 10;21(46):7001-10.

11.

AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.

Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA 3rd, Keats JA, Sawyer TK, Gallick GE.

Mol Cancer Ther. 2005 Dec;4(12):1900-11.

12.

Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.

Ueda Y, Igishi T, Hashimoto K, Suyama H, Araki K, Sumikawa T, Takeda K, Nakazaki H, Matsunami K, Kodani M, Shigeoka Y, Matsumoto S, Shimizu E.

Int J Oncol. 2009 Mar;34(3):689-96.

PMID:
19212674
13.

Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.

Dalgarno D, Stehle T, Narula S, Schelling P, van Schravendijk MR, Adams S, Andrade L, Keats J, Ram M, Jin L, Grossman T, MacNeil I, Metcalf C 3rd, Shakespeare W, Wang Y, Keenan T, Sundaramoorthi R, Bohacek R, Weigele M, Sawyer T.

Chem Biol Drug Des. 2006 Jan;67(1):46-57.

PMID:
16492148
14.

An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.

He H, Hirokawa Y, Levitzki A, Maruta H.

Cancer J. 2000 Jul-Aug;6(4):243-8.

PMID:
11038144
15.

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation.

Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok BA, Connelly PA.

J Biol Chem. 1996 Jan 12;271(2):695-701.

16.

Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth.

Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker AJ, Corey SJ.

Leukemia. 1999 Jun;13(6):855-61.

PMID:
10360372
17.

Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.

Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, Gallick GE.

Clin Cancer Res. 2004 Feb 15;10(4):1545-55.

18.

Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).

Hirokawa Y, Levitzki A, Lessene G, Baell J, Xiao Y, Zhu H, Maruta H.

Cancer Lett. 2007 Jan 8;245(1-2):242-51.

PMID:
16540233
19.

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.

Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA.

Cancer Res. 2007 Feb 15;67(4):1580-8.

20.

Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.

Kansra S, Stoll SW, Johnson JL, Elder JT.

Mol Pharmacol. 2005 Apr;67(4):1145-57.

Items per page

Supplemental Content

Support Center